IIOT-OXYS, Inc. Enters into NDA with New England-Based Biotech Start-Up

Rhea-AI Summary

IIOT-OXYS, Inc. (OTC PINK: ITOX) announced a Non-Disclosure Agreement with a New England biotechnology start-up focused on innovative medical device implants currently in clinical trials. This marks the second NDA executed in two months, indicating an expansion in their pharmaceutical manufacturing segment. CEO Cliff Emmons expressed enthusiasm about leveraging IIOT-OXYS's technology for enhancing manufacturing processes. The company aims to use its edge computing and machine learning algorithms to add significant value to the client's biomanufacturing operations.

Positive

• Execution of NDA with a biotechnology start-up enhances business opportunities.
• Expansion of the pharmaceutical intelligent manufacturing segment indicates growth potential.
• Previous successful engagements with notable companies signal credibility and experience in the sector.

Negative

• Forward-looking statements indicate risks such as loss of major customers and inability to secure new contracts.

CAMBRIDGE, MA / ACCESSWIRE / February 24, 2021 / IIOT-OXYS, Inc. (OTC PINK:ITOX) announced the execution of a Non-Disclosure Agreement (NDA) with a New England based biotechnology start-up.

Cliff Emmons, CEO of IIOT-OXYS, Inc., stated, "This customer manufactures novel medical device implants, which are currently undergoing clinical trials. The company has been operating for over a decade and received significant funding within the past year to fund operations, clinical trials, and regulatory approval of their devices. Our customer engagement process consists of several steps, the first being the execution of an NDA, which then allows us to quickly define a problem statement of interest to the client, which then leads to a definition of scope of work for the first contract. We are very pleased to be working with this innovative company that can leverage our technology to ensure the quality and productivity of their manufacturing processes. We look forward to working with their domain experts to see where our edge computing and machine learning algorithms will add the most value to their biomanufacturing products and processes."

"This is the second such agreement within the past two months, which continues to represent an expansion of our current pharmaceutical intelligent manufacturing segments. As previously disclosed, in Q1 of 2020 we successfully completed a pilot program with a Fortune 500 Pharma company, and signed a collaboration agreement with Aingura IIoT, S.L. These two accomplishments have allowed the Company and its partner to prepare use cases to renew engagements with all of the Company's earlier prospects and reach out to new ones. Our sales and marketing efforts continue to result in expanding our key targeted markets and serving a diverse group of clients. We expect these agreements to lead to new business in due time," continued Mr. Emmons.

Forward-Looking Statements

This news release contains forward-looking statements that reflect Management's current views about future events and financial performance. Forward-looking statements often contain words such as ''expects,'' ''anticipates,'' ''intends,'' or ''believes.'' Our forward-looking statements are subject to a number of risks and uncertainties that may cause actual results and events to differ materially from those projected in the forward-looking statements. Risks and uncertainties that could adversely affect us include, without limitation, the loss of major customers, our failure to obtain new contracts, our inability to patent products or processes, our infringement of patents held by others, our inability to finance our business and the other risks and uncertainties that are discussed in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this news release are made only as of the date of this news release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.

About Us

IIOT-OXYS, Inc. is a technology company at the intersection of IIoT, AI & Machine Learning, Edge Computing and Manufacturing Operations. We provide actionable mission-critical insights for the Medical/Pharmaceutical, Manufacturing, Agriculture, Defense, and Structural Health, and other industries. IIOT-OXYS, Inc. edge computing open-source hardware and proprietary ML algorithms employ our Minimally-Invasive Load Monitoring (MILM) technology to simply gather data and gain insights to monitor, scope, move from preventive to predictive maintenance, and even optimize development and manufacturing processes. For additional information visit www.oxyscorp.com

CONTACT:

Clifford L. Emmons
CEO
IIOT-OXYS, Inc.
contact@oxyscorp.com
www.oxyscorp.com

SOURCE: IIOT-OXYS, Inc.

View source version on accesswire.com:
https://www.accesswire.com/631693/IIOT-OXYS-Inc-Enters-into-NDA-with-New-England-Based-Biotech-Start-Up

FAQ

What is the significance of the NDA signed by IIOT-OXYS, Inc. with a biotech start-up?

The NDA with a biotech start-up signifies a potential growth opportunity in the medical device sector and an expansion in IIOT-OXYS's pharmaceutical manufacturing operations.

How does IIOT-OXYS plan to utilize its technology for the new client?

IIOT-OXYS intends to apply its edge computing and machine learning algorithms to enhance the manufacturing processes of the client's medical device implants.

What are the recent developments for IIOT-OXYS, Inc. in terms of partnerships?

IIOT-OXYS has executed two NDAs recently, indicating active expansion and engagement in the pharmaceutical manufacturing sector.

What risks are associated with the forward-looking statements made by IIOT-OXYS, Inc.?

The forward-looking statements outline risks such as potential loss of major customers and challenges in obtaining new contracts, which could adversely affect the company's performance.